• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket

    9/22/22 6:34:35 AM ET
    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    EDP Services
    Technology
    Get the next $ACOR alert in real time by email

    Gainers

    • Spero Therapeutics, Inc. (NASDAQ:SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.
    • HeartBeam, Inc. (NASDAQ:BEAT) shares rose 27.8% to $2.02 in pre-market trading after dropping 16% on Wednesday. Heartbeam recently announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
    • American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) rose 20.1% to $0.2590 in pre-market trading.
    • Taoping Inc. (NASDAQ:TAOP) rose 19.7% to $0.73 in pre-market trading. Taoping recently posted 1H revenue of $10.5 million.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) rose 18.4% to $0.3672 in pre-market trading after declining around 7% on Wednesday.
    • Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) rose 15.8% to $1.90 in pre-market trading after dropping over 5% on Wednesday.
    • Organovo Holdings, Inc. (NASDAQ:ONVO) rose 15.3% to $2.45 in pre-market trading.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) rose 12% to $0.2660 in pre-market trading after declining 5% on Wednesday.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) rose 11.2% to $1.98 in pre-market trading after declining over 4% on Wednesday.
    • Timber Pharmaceuticals, Inc. (NYSE:TMBR) rose 10.3% to $0.1138 in pre-market trading. Timber Pharmaceuticals recently received positive opinion on Orphan Designation from European Medicines Agency For TMB-001.
    • SmartRent, Inc. (NYSE:SMRT) rose 8.1% to $2.93 in pre-market trading after gaining around 7% on Wednesday.
    • Deutsche Bank Aktiengesellschaft (NYSE:DB) rose 6.3% to $9.14 in pre-market trading. Deutsche Bank said its New York Branch, Deutsche Bank New York, and its affiliate Deutsche Bank Trust Company Americas have raised their prime lending from 5.50% to 6.25%.

     

    Don’t forget to check out our premarket coverage here .

    Losers

    • Soluna Holdings, Inc. (NASDAQ:SLNH) fell 11.9% to $1.48 in pre-market trading after gaining around 6% on Wednesday.
    • Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares fell 11.6% to $0.6899 in pre-market trading after jumping 10% on Wednesday. Tiziana Life Sciences announced purchase of 20,145 common shares by Executive Chairman.
    • ECMOHO Limited (NASDAQ:MOHO) fell 9.4% to $0.1580 in pre-market trading after jumping over 50% on Wednesday.
    • China Pharma Holdings, Inc. (NYSE:CPHI) shares fell 8.6% to $0.1411 in pre-market trading.
    • Evaxion Biotech A/S (NASDAQ:EVAX) fell 8.5% to $2.13 in pre-market trading. Evaxion Biotech shares gained 14% on Wednesday after the company announced it reached an important milestone announcing today that it had enrolled its first patient in the global phase 2b clinical trial of EVX-01.
    • Brenmiller Energy Ltd (NASDAQ:BNRG) fell 7.7% to $3.56 in pre-market trading.
    • FOXO Technologies Inc. (NYSE:FOXO) fell 7.1% to $2.08 in pre-market trading after gaining over 6% on Wednesday.
    • Novavax, Inc. (NASDAQ:NVAX) fell 5.3% to $24.50 in pre-market trading. JP Morgan downgraded Novavax from Neutral to Underweight and lowered the price target from $132 to $27.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 4.3% to $5.56 in pre-market trading after declining 5% on Wednesday.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AVCT
    $BEAT
    $BNRG

    CompanyDatePrice TargetRatingAnalyst
    Deutsche Bank AG
    $DB
    4/20/2026Overweight → Equal Weight
    Barclays
    Heartbeam Inc.
    $BEAT
    4/20/2026Buy → Hold
    D. Boral Capital
    Heartbeam Inc.
    $BEAT
    3/31/2026$4.00Buy
    B. Riley Securities
    Heartbeam Inc.
    $BEAT
    3/27/2026$5.00Buy
    D. Boral Capital
    Heartbeam Inc.
    $BEAT
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Soluna Holdings Inc.
    $SLNH
    12/11/2025$5.00Neutral → Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bohjalian Thomas N bought $260,490 worth of shares (150,000 units at $1.74), increasing direct ownership by 43% to 500,000 units (SEC Form 4)

    4 - SmartRent, Inc. (0001837014) (Issuer)

    3/12/26 6:25:23 PM ET
    $SMRT
    EDP Services
    Technology

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Martell Frank bought $103,244 worth of shares (50,000 units at $2.06) (SEC Form 4)

    4 - SmartRent, Inc. (0001837014) (Issuer)

    12/16/25 4:30:22 PM ET
    $SMRT
    EDP Services
    Technology

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank downgraded by Barclays

    Barclays downgraded Deutsche Bank from Overweight to Equal Weight

    4/20/26 8:23:07 AM ET
    $DB
    Major Banks
    Finance

    HeartBeam downgraded by D. Boral Capital

    D. Boral Capital downgraded HeartBeam from Buy to Hold

    4/20/26 8:06:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on HeartBeam with a new price target

    B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    3/31/26 8:12:24 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    SEC Filings

    View All

    SEC Form 424B3 filed by Soluna Holdings Inc.

    424B3 - Soluna Holdings, Inc (0000064463) (Filer)

    4/22/26 4:30:16 PM ET
    $SLNH
    EDP Services
    Technology

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    4/22/26 7:00:08 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Soluna Holdings Inc.

    EFFECT - Soluna Holdings, Inc (0000064463) (Filer)

    4/22/26 12:15:22 AM ET
    $SLNH
    EDP Services
    Technology

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Cruickshank Tim

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:21 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Elfrink Willem

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:07 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Jaff Michael R

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:47:53 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of American Tungsten & Antimony Limited

    Deutsche Bank announced today its appointment as depositary bank for the American Depositary Receipt program of American Tungsten & Antimony Limited. American Tungsten & Antimony Limited (OTC:ATAYY) is an ASX-listed critical minerals company ((ASX: AT4, OTCQB:ATALF) focused on the exploration and development of antimony and tungsten projects in the United States. The company's portfolio includes the flagship Antimony Canyon Project in Utah, together with a portfolio of tungsten projects across Utah and Nevada including Tennessee Mountain, Fraction Lode, Nightingale and Dutch Mountain. The company is pursuing a U.S.-based hub-and-spoke processing and refining strategy aligned with U.S. Gov

    4/23/26 4:05:00 PM ET
    $DB
    Major Banks
    Finance

    Ocular Therapeutix™ to Host Investor Day on June 17, 2026

    BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced plans to host an Investor Day on Wednesday, June 17, 2026, in New York City. Click here to register for the live event, with virtual access available, which will begin at 2:00 PM ET. The Investor Day will include participation from Ocular Therapeutix senior leadership and prominent retinal disease key opinion leaders. Additional details will be provided in advance of the event. A live webcast of the presentation will be available on the "Events and Presentations" section of the Company'

    4/22/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soluna Announces Fourth Expansion with Blockware, Surpassing 17 MW of Total Capacity

    New 3.3 MW deployment marks Blockware's first presence at Project Dorothy 1B Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ:SLNH), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, today announced a new expansion of its partnership with Blockware. The agreement adds 3.3 MW of capacity at Soluna's Project Dorothy 1B site in West Texas. This marks Blockware's fourth expansion with Soluna and its first deployment at Project Dorothy 1B. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421426186/en/ With this latest addition, Blockware becomes the first customer sig

    4/21/26 7:30:00 AM ET
    $SLNH
    EDP Services
    Technology

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Leadership Updates

    Live Leadership Updates

    View All

    Flow Sciences Appoints Michael Gesser as Chief Financial Officer

    Life Sciences Finance Veteran and Flow Sciences Board Member Steps Into CFO Role to Support Company's Next Phase of GrowthRALEIGH, N.C, April 8, 2026 /PRNewswire/ -- Flow Sciences, Inc., a global leader in advanced containment solutions for laboratory and pharmaceutical environments, today announced the appointment of Michael Gesser as its chief financial officer. Gesser, who has served as a member of the Flow Sciences board of directors since 2021, will continue serving on the board while assuming executive responsibility for all finance, accounting, tax, treasury, FP&A and investor relations functions.

    4/8/26 8:00:00 AM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

    Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline  GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr. Walker now reports to John C. Jacobs, President and Chief Executive Officer of Novavax.A specialist in internal medicine and pulmonary and critical care medi

    3/30/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Financials

    Live finance-specific insights

    View All

    SmartRent to Report First Quarter 2026 Financial Results on May 6, 2026

    SmartRent, Inc. (NYSE:SMRT) ("SmartRent" or the "Company"), the leading provider of smart communities solutions and smart operations solutions for the rental housing industry, today announced it will release first quarter 2026 results and host a conference call on Wednesday, May 6, 2026. First Quarter 2026 financial results will be released before the market opens, and at 11:30 a.m. ET, Frank Martell, the Company's President and Chief Executive Officer, and Daryl Stemm, Chief Financial Officer, will host a conference call and webcast to discuss the Company's performance. The press release and supporting materials will be available in the Events and Presentations section of the Company's Inv

    4/16/26 10:00:00 AM ET
    $SMRT
    EDP Services
    Technology

    Soluna Acquires Full Ownership of Project Dorothy 1A, Accelerating Vertical Integration and AI Campus Development

    $16.5M acquisition consolidates Dorothy campus control; positions Soluna to convert existing infrastructure to AI and market Dorothy 3 to prospective customers Soluna Holdings, Inc. ("Soluna" or the "Company") (NASDAQ:SLNH), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, today announced the acquisition of Spring Lane Capital's equity interest in Project Dorothy 1A ("D1A") for $16.5 million. The transaction gives Soluna complete equity ownership of D1A, located in Silverton, Texas, and marks the second major step in the Company's vertical integration of the Dorothy campus, following the $53 million acquisition of the Briscoe Wind Fa

    4/16/26 7:30:00 AM ET
    $SLNH
    EDP Services
    Technology

    Brenmiller Energy Ltd. Announces Expected Implementation of 5-for-1 Reverse Share Split

    Rosh Ha'ayin, Israel--(Newsfile Corp. - April 10, 2026) - Brenmiller Energy Ltd. (NASDAQ:BNRG) ("Brenmiller", "Brenmiller Energy" or the "Company"), a leading global provider of Thermal Energy Storage ("TES") solutions for industrial and utility customers, today announced that a reverse share split of its issued and outstanding ordinary shares, no par value per share (the "Ordinary Shares") at a ratio of 5-for-1 is expected to be implemented after market close on April 14, 2026. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on April 15, 2026 under the Company's existing trading symbol "BNRG".The reverse share split was

    4/10/26 4:30:00 PM ET
    $BNRG
    Building Products
    Industrials

    $ACOR
    $AVCT
    $BEAT
    $BNRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care